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Background: The progression of cancer through stages that guide a benign hyperplastic epithelial tissue towards a
fully malignant andmetastatic carcinoma, is driven by genetic andmicroenvironmental factors that remodel the
tissue architecture. The concept of epithelial–mesenchymal transition (EMT) has evolved to emphasize the
importance of plastic changes in tissue architecture, and the cross-communication of tumor cells with various
cells in the stroma and with speciﬁc molecules in the extracellular matrix (ECM).
Scope of the review: Among themultitude of ECM-embedded cytokines and the regulatory potential of ECMmol-
ecules, this article focuses on the cytokine transforming growth factor β (TGFβ) and the glycosaminoglycan
hyaluronan, and their roles in cancer biology and EMT. For brevity, we concentrate our effort on breast cancer.
Major conclusions: Both normal and abnormal TGFβ signaling can be detected in carcinoma and stromal cells, and
TGFβ-induced EMT requires the expression of hyaluronan synthase 2 (HAS2). Correspondingly, hyaluronan is a
major constituent of tumor ECM and aberrant levels of both hyaluronan and TGFβ are thought to promote a
wounding reaction to the local tissue homeostasis. The link between EMT and metastasis also involves the
mesenchymal–epithelial transition (MET). ECM components, signaling networks, regulatory non-coding RNAs
and epigenetic mechanisms form the network of regulation during EMT-MET.
General signiﬁcance: Understanding the mechanism that controls epithelial plasticity in the mammary gland
promises the development of valuable biomarkers for the prognosis of breast cancer progression and even
provides new ideas for a more integrative therapeutic approach against disease. This article is part of a Special
Issue entitled Matrix-mediated cell behaviour and properties.
© 2014 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
It has long been understood that epithelial tumors lose their tissue
organization, become dedifferentiated and secrete abnormal quantities
of extracellular matrix (ECM) in a process that resembles wound
healing, and which connects to the invasive and metastatic capacity of
the primary tumor [1]. Related to these events is the process of epithe-
lial–mesenchymal transition (EMT),whichhas biological relevancedur-
ing early embryonic development and later organogenesis, and which
can also be activated during wound healing in ﬁbrotic or cancer tissues
that experience chronic inﬂammatory stress [2]. The term “transition”
in EMT, emphasizes the transient and reversible nature of the process,
so that under speciﬁc conditions within the tissue, mesenchymal cells
can also undergo the inverse plastic change that generates epithelial-mediated cell behaviour and
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. Open access under CC BY-NC-ND licetissue, so called, mesenchymal–epithelial transition (MET). Key cellular
alterations that occur during EMT are the loss of cell–cell adhesions, the
change in supporting cellular polarity so that the apico-basal differenti-
ation of epithelial cell membranes is destroyed, the new interactions
between new plasmamembrane receptors and remodeled constituents
of the ECM, all being important changes that support collective or even
individual cell migration and a more plastic, so-called mesenchymal
overall cell identity [3]. Developmental examples of EMT are the mor-
phogenetic processes of gastrulation and neural crest formation, lung
organogenesis and specialized tissue formation such as the heart valve
cushions [3]. During chronic inﬂammation, tissues can become either ﬁ-
brotic, exhibiting excessive synthesis and deposition of ECM, or cancer-
ous, exhibiting again remodeled matrix and enhanced capacity for cell
motility [3,4]. Furthermore, EMT is thought to facilitate the extracellular
microenvironment that fosters stem cell proliferation and maintenance
in the context of cancer development [5]; EMT endows cancer cells
with resistance to oncogene-induced senescence and chemo- or radio-
therapeutic regimes, thus contributing to the generation and propaga-
tion of so-called cancer stem cells that are responsible for the
long-term maintenance and metastatic dissemination of this disease
[6–8]. Many of the key contributions of EMT in cancer progressionnse.
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in vitro and in human specimens and for this reason our analysis will
focus on this speciﬁc group of human malignancy.
2. Molecular factors that regulate EMT
It is nowwell established that alterations in the ECM including inter-
stitial matrix and the specialized basement membrane, are closely cor-
related to tumor progression. During the progression of breast
carcinomas the epithelial cells as well as the cells of the stroma increase
the synthesis of ECM components, resulting in changes in the composi-
tion and thereby structure of thematrix [9], as illustrated by histological
and biochemical studies [10–14]. Notably, the tumor stroma resembles
the stroma during embryonic development, which is rich in glycosami-
noglycans and promotes cellular proliferation and migration [1,15].
Themammary glands are composed of bilayered ductal structures of
outer myoepithelial cells, inner luminal cells and mammary stem cells
that reside between these two populations, adipose cells, ﬁbroblasts,
endothelial cells, immune cells and ECM. ECM components include
collagens, laminins, proteoglycans, ﬁbronectin, tenascins, elastin and
glycosaminoglycans [13,16]. The basement membrane is a specialized
ECM that separates epithelial, endothelial cells and adipocytes from
the stroma [16,17]. During tumor progression the ECM composition and
structure aremodiﬁed by inﬁltratingmast cells, leukocytes, macrophagesFig. 1. The EMT–MET program (partial overview). Five regulatory modules that induce or co
regulators, transcription factors, splicing and translation factors and non-coding RNAs. Below
architecture, organization, expression or function changes during EMT–MET and cancer stem
proteins, the ECM and adhesion molecules, the secreted cytokines, chemokines and receptors,
in this review are listed. Factors that induce EMT are shown in red whereas factors that induce
green.and “activated” ﬁbroblasts that release growth factors, cytokines,
chemotactic factors and proteolytic enzymes and exhibit increased
biosynthetic activity of ECM components. In particular, elevated pro-
duction of the ECM components hyaluronan, versican and collagen is
prominent in breast tumor stroma [18–22]. In breast cancer, the ECM
is enriched in many new constituents, mainly proteins such as speciﬁc
collagen and ﬁbronectin isoforms and secreted growth factors such as
transforming growth factor β (TGFβ) and ﬁbroblast growth factors
(FGFs) that have an impact on the tumor cells by facilitating the onset
and maintenance of EMT. These changes in the microenvironment
prepare the evolving tumor tissue so that tumor cells can invade locally
[5]; moreover, blood and lymphatic vessels are recruited towards the
tumor and some tumor cells manage to intravasate into the recruited
vessels [23]. Understanding how the altered composition of the ECM
determines the de-regulatedmechanismsduring breast cancer invasion
and metastasis is of utmost importance.
A growing list of molecular and environmental cues can initiate the
EMT [3] (Fig. 1). Smoking, hypoxic conditions and ultraviolet radiation
are established inducers of EMT, which usually operates by activating
or mediating the secretion of a cohort of growth factors, cytokines and
chemokines that induce the EMT process via activation of their respec-
tive signaling pathways [3]. For example, during breast cancer progres-
sion, estrogens inhibit the EMT and promote epithelial differentiation,
but when estrogen receptor expression is misregulated, hypoxicntrol EMT and MET are shown on top. These modules are signal transducers, chromatin
, ﬁve distinct but also inter-related functional modules include lists of molecules whose
ness. These modules are the cell–cell junction proteins, the cytoskeleton and trafﬁcking
and the cancer stemness regulators. In each module, molecular players that are discussed
MET are shown in blue; other factors that may regulate either process are listed in black or
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expression of, and mediates crosstalk with, components of the path-
ways of Notch, insulin-like growth factor, interleukin-like EMT inducer
(ILEI) and vascular endothelial growth factor, promoting a sustained
EMT that fosters cancer metastasis [24].
Many of these signaling pathways, e.g. TGFβ, FGF and Notch lead to
the upregulation of speciﬁc embryonic transcription factors, whose
normal action is not only to promote the EMT during embryonic devel-
opment, but also to facilitate EMT and invasiveness in breast cancer. The
so-called EMT transcription factors (EMT-TFs) are zinc ﬁnger proteins,
such as the transcriptional repressors Snail (SNAI1) [25,26] and Slug
(SNAI2) [27,28]; zinc ﬁnger and homeobox domain proteins, such as
δEF1/ZEB1 [29] and SIP1/ZEB2 [30]; basic helix–loop–helix (bHLH) pro-
teins such as E47 [31] and Twist1 [32] transcription factors. In addition,
the chromatin protein high-mobility group A2 (HMGA2) integrates
EMT signals downstream of TGFβ in breast cancer cell lines, and coordi-
nates the transcriptional induction of Snail, Slug, Twist1 and the repres-
sion of the inhibitor of differentiation ID2 [33–35]. The molecular
networks that coordinate the expression and function of the EMT-TFs
in breast cancer are being understood at increasingly deeper levels
[36], and speciﬁc examples will be listed below under the action of
TGFβ.
3. TGFβ induces mammary EMT
The mechanisms and pathways that mediate signaling by TGFβ and
initiate or maintain the EMT program have been studied over the years
[37,38]. Induction of EMT by TGFβ represents one of the key cell biolog-
ical processes that mediate pro-tumorigenic actions by this cytokine,
while TGFβ is also known to act as a tumor suppressor by promoting
epithelial tissue homeostasis and safeguarding tissues from abnormal
growth prior to cancer advancement towards the aggressive and inva-
sive stage [39]. Some useful in vitro cell models of mammary epithelial
cells that undergo robust EMT in response to TGFβ have been instru-
mental for our current understanding of signaling mechanisms that
contribute to EMT. Among such models, the Namru murine mammary
gland (NMuMG) cell line is very sensitive to TGFβ signaling and
shows robust and reversible EMT responses [40–42]; the mouse EpH4
cell line, when transformed with oncogenic H-Ras (generating the
EpRas model), undergoes a very stable and irreversible EMT that de-
pends on autocrine TGFβ [43]; more recently the mouse Py2T cell line
also shows robust and reversible EMT response [44]. The NMuMG cell
model has also been exploited to generate the ﬂuorescently labeled
Fucci model that allows in vivo monitoring of the phase of the cell
cycle [45]; however, NMuMG cells fail to generate xenografts in immu-
nocompromised mice and thus cannot contribute to correlative studies
of EMT and cancer metastasis [40,45]. Both EpRas and Py2T cell models
are compatiblewith in vivo studies of cancer progression andmetastasis
[43,44].
4. Importance of non-Smad signaling in EMT
The TGFβ signaling pathways commonly start by ligand binding to
the heteromeric type II/type I receptor serine/threonine kinase
complex, and these two receptors subsequently mediate different
types of signals that foster the EMT response [46].We commonly divide
the receptor-initiated signals into non-Smad and Smad signaling path-
ways based on the profound importance of the Smad family of signal
transducers that mediate many of the TGFβ signals. We ﬁrst discuss ex-
amples of non-Smad signaling in EMT. TGFβ activates its type II receptor
kinase, which phosphorylates the polarity complex protein Par6, lead-
ing to recruitment of the ubiquitin ligase Smurf1 that ubiquitylates
and degrades the small GTPase RhoA, thus causing local depolymeriza-
tion of actin microﬁlaments at the apical junctions of mammary epithe-
lial cells, and subsequent disassembly of the tight and adherens
junctions at the plasmamembrane, thus initiating the EMT [47]. Recentdeeper evaluation of this mechanism demonstrates that one of the po-
larity complex enzymes, the atypical protein kinase C ι (PKCι) also
makes a complex with the TGFβ receptors and potentiates the phos-
phorylation of Par6 by the type II receptor kinase [48]. The TGFβ type I
receptor also provides non-Smad signals, as for example, upon
recruitment of the ubiquitin ligase TRAF6, activation of proteases leads
to cleavage of the receptor and translocation of the cytoplasmic kinase
domain of this receptor to the nucleus, where it binds to chromatin
and together with the transcriptional co-activator p300 induces the
expression of EMT-TFs like Snail [49]. In addition, studies in NMuMG
cells and in breast cancer cell lines have linked the TGFβ type I
receptor with downstream activation of many key signaling enzymes
that provide essential signals towards EMT, and include the phos-
phatidylinositol 3′ kinase (PI3K)/AKT kinase pair [50], the Src tyrosine
kinase and the mitogen activated protein kinase (MAPK) p38 [51,52],
the focal adhesion kinase (FAK)whose signaling is coupled to activation
of the integrin-β1 [53,54], the Rho family of small GTPases [53], and
more [55]. A prominent and more recent pathway that mediates EMT
signals downstream of TGFβ is the mammalian target of rapamycin
(mTOR) kinase pathway, which is directly coupled to the PI3K [56].
Accordingly, TGFβ type I receptor signaling couples to the PI3K leading
to activation of the mTOR complex 2 (mTORC2), whose activity is
required for EMT-TF activation and breast cancer cell migration. For
this reason, inhibition of mTOR kinase activity could effectively block
in vivo metastasis of breast cancer cells [56]. The activation of
mTORC2 by TGFβ also involves another kinase, the integrin-like kinase
(ILK) that forms complexes withmTORC2 in response to TGFβ and inhi-
bition of ILK activity, similar to mTORC2 inhibition, negatively impacts
on EMT and cell invasiveness [57]. Interestingly, an RNAi screen
revealed that the mTORC1 kinase complex is required for epithelial
differentiation of mammary cells, and downregulation of mTORC1 po-
tently promoted EMT-TF (ZEB1, ZEB2) expression and EMT [58]. TGFβ
signaling via the PI3K also affects mTORC1 kinase activity and this
regulates cell size and overall levels of protein synthesis in mammary
epithelial cells whose cell cycle is arrested by TGFβ [59]. Thus, the two
mTOR complexes, mTORC1 and mTORC2 are important in the process
of EMT during breast cancer progression and mTOR kinase inhibitors
may be useful as part of a cocktail against breast cancer metastasis. A
ﬁnal and novel aspect of non-Smad signaling that controls the EMT
response to TGFβ that we discuss here is the role of the cyclin-
dependent kinase 5 (CDK5) [60]. CDK5 potentiates the TGFβ signal
that initiates EMT at least in part by controlling FAK kinase phosphory-
lation, and thus leading to breast cancer cellmigration and invasion. The
fact that CDK5 is highly expressed inmany breast cancers also correlates
with an overactivity of TGFβ signaling in these cancers and offers
another druggable target in the panoply of anti-invasive drugs that are
currently under development. Another contribution of the PI3K/AKT
signaling axis to EMT is the direct phosphorylation of the EMT-TF
Twist1 by AKT, which promotes Twist1 transcriptional activity [61].
Interestingly, one of the target genes of the AKT-activated Twist1 is
the gene for the TGFβ2 ligand,which is induced and promotes sustained
autocrine TGFβ signaling and metastasis [61].
5. Smad-mediated transcriptional control of EMT
As outlined in the previous section, one of the best understood
scenarios of EMT downstream of TGFβ signals that operate in breast
epithelial cells involves Smad signaling and transcriptional regulation
of a cohort of EMT-TFs [38]. Our original ﬁnding that TGFβ induces the
embryonic chromatin factor HMGA2 via Smad signaling to elicit EMT
[33–35] (Fig. 2), has now been conﬁrmed by independent studies also
demonstrating in vivo that HMGA2 overexpression causes metastasis
of various breast cancer models [62]. We identiﬁed HMGA2 as an
immediate-early and direct target of TGFβ/Smad signaling, and the
study of Morishita et al. also uncovered that HMGA2 could regulate the
expression of the TGFβ type II receptor, presumably via a chromatin-
Fig. 2. Suggestedmechanisms in TGFβ-inducedEMT. TGFβ signals via its heteromeric receptor complex (TβR) to activate Smads,which then leads to direct transcriptional regulation of the
HMGA2 gene. Furthermore, TGFβ-activated Smad and MAPKs (ERK, p38), together with newly synthesized HMGA2 are required for the transcriptional induction of Snail, while HMGA2
also contributes to the transcriptional induction of Twist1. In addition, TGFβ-dependent induction of HAS2 expression, in a Smad-dependent and Smad-independentmanner, is important
in TGFβ-induced EMT. Experimentally deﬁned regulatory sequences in the promoters of HMGA2, Snail, Twist1 and HAS2 genes are indicated, while unknown transcription factor binding
sites are shownwith a question mark. Transcriptional activation of the HAS2 gene leads to enhanced HAS2 protein expression and hyaluronan production. Upon their induction by TGFβ,
the Snail and Twist transcription factors as well as HAS2 molecules contribute to the EMT response of mammary epithelial cells.
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regulatory loop between TGFβ, HMGA2 and one of the major TGFβ re-
ceptors [62]. Earlier evidence that the related protein HMGA1 could pro-
mote mesenchymal differentiation and invasiveness in breast cancer
cells [63], was recently expanded to several examples of basal-like breast
cancer cell models, emphasizing the role of HMGA1 as a keymediator of
themesenchymal state and of associated stem-like and self-renewal fea-
tures (as will be discussed later) [64]. One of the direct targets of TGFβ/
Smad signaling and of HMGA2 transcriptional regulation is the Snail
gene [34].
An emerging area in the EMT ﬁeld is the necessity of epigenetic
regulation at a genome-wide level for EMT to be elicited and for the
EMT-TFs to properly function, a fact that collectively is now referred
to as nuclear reprogramming during EMT [65]. Accordingly, transcrip-
tional repression by Snail requires the direct function of the interacting
histone tail methyltransferase G9a and cooperating DNA methyltrans-
ferases in a large set of breast cancer cell lines and primary breast cancer
samples [66]. Interestingly, one of the direct gene targets of Snail
and chromatin-based co-repressor complexes is the glycolytic gene
fructose-1,6-biphosphatase 1 (FBP1) [67]. Snail-mediated repression of
FBP1 during EMT in basal-like breast cancers mediates in part the well
knownWarburg effect and thus promotes metabolic switch and stem-
like growth properties to cancer cells. In a similar manner, mammary
epithelial cells that exhibit robust EMT due to Twist1 overexpression
also exhibit dramatic genome-wide changes in the methylation pattern
of histone tails and of DNA, in a locus-speciﬁc manner [68]. Epigenetic
control of the breast cancer genome by Twist1 appears to require the
cooperation of the EZH1 and EZH2 histone tail methyltransferases.
Regulation of histone tail modiﬁcations by EMT-TFs is very dynamic
and gene-speciﬁc, as exempliﬁed by the involvement of the histone
demethylase KDM6B/JMJD3, which positively contributes to TGFβ-
induced EMT in mammary epithelial cells, in part by facilitating the
transcriptional induction of Snail [69]. Demethylation operates not
only on histone tails, but also at the DNA level and the activation-
induced cytidine deaminase (AID) that demethylates methylatedcytidines, plays positive roles in the induction of EMT in immortalized
mammary epithelial and breast cancer cells by supporting the transcrip-
tional induction of several EMT-TFs [70].
More proximal to the core components of TGFβ signaling, the
mediator subunit MED12 was found to be frequently mutated and
inactivated in human cancers, including breast cancer [71]. Loss of
MED12 derepresses TGFβ type II receptor expression via a cytoplasmic
mechanism where MED12 sequesters the receptor, and enhanced
TGFβ signaling contributes to EMT and drug resistance, a common
feature of cancer stem cells. This mechanism strongly proposed that
combinatorial therapy against the TGFβ receptor and another pathway
in cancer cells has synergistically beneﬁcial effects at least in vitro. In
a functionally similar but distinct mechanism, the nicotinamide–
adenine–dinucleotide-dependent deacetylase SIRT1 protectsmammary
epithelial cells and breast cancer cells from EMT and metastasis by
deacetylating Smad4, and thus limiting the transcriptional activity of
thismajormediator of TGFβ signaling [72]. A similarmechanism targets
Smad3, another signaling mediator of TGFβ pathways, and involves the
ubiquitin ligase DEAR1/TRIM62, which ubiquitylates and degrades
Smad3 [73]. In breast and other types of cancer, the DEAR1 gene is mu-
tated by loss-of-function mutation, leading to oncogenic progression,
enhanced TGFβ signaling (due to loss of negative regulation of Smad3)
and subsequent EMT, invasiveness and metastasis in vivo. A DEAR1–
Slug gene duowas shown to serve as a faithful predictor of poor survival
in invasive breast carcinoma [73]. Using a different mechanism of
positive feedback towards TGFβ ligand expression, the Krüppel-like
zincﬁnger transcription factor ZNF217 is oncogenicallymutated in inva-
sive and metastatic breast cancer and causes EMT and migration
upon overexpression in mammary epithelial cells [74]. ZNF217 causes
misexpression of TGFβ, and abnormal activation of its signaling
pathway; for this reason, TGFβ receptor inhibition can effectively block
the pro-invasive and metastatic effects of oncogenic ZNF217.
However, it should bemade clear that in addition to themajor EMT-
TFs and direct modulation of the TGFβ–Smad function, a large cohort of
transcription factors cooperates with Smads or gets induced by TGFβ
2625A. Moustakas, P. Heldin / Biochimica et Biophysica Acta 1840 (2014) 2621–2634and participates in regulation of speciﬁc genes that impact on the EMT
program inmammary epithelial cells. Such a recent prominent example
is the homeobox transcription factor Sox4, which is highly expressed in
a subset of triple-negative breast cancers and causes activation of TGFβ
signaling, while TGFβ induces Sox4 expression [75]. The end result is
mesenchymal differentiation and breast cancer stem cell accumulation,
which relates with enhanced tumor progression in vivo and enhanced
cell invasiveness. Interestingly, the transcriptional program regulated
by Sox4 during EMT appears to include only mesenchymal genes, such
as vimentin, ﬁbronectin and N-cadherin [76], and the histone methyl-
transferase EZH2 that is important for the pro-survival signals generat-
ed during EMT [77]. Since EZH2 overexpression in breast cancer
cells where Sox4 has been silenced recapitulates the EMT response
[77], it is reasonable to suggest that Sox4-induced EZH2 may be re-
quired for the full activity of Twist1 in inducing the mesenchymal
gene program [68].
Probably the most prominent transcription factor family that partic-
ipates in the EMT response and mediates transcriptional induction of
themesenchymal and ECMprogram in breast cancer cells, aremembers
of the activation protein 1 (AP1) family [78]. The AP1 family includes
many bHLH members that form heteromeric complexes and regulate
a large number of genes, while, many of these family members are
immediate-early gene targets of TGFβ signaling and somedirectly inter-
actwith Smads [79]. Possibly, one of themost prominent transcriptional
complexes that regulates breast cancer invasiveness and mesenchymal
gene expression is the Smad2/3–Fra1 complex [79], a ﬁnding that
deserves deeper analysis and generalization to a large group of breast
cancers. In addition to or possibly in associationwith AP1, the transcrip-
tional regulator NFAT can also contribute to the regulation of invasive-
ness and matrix degradation during EMT [80]. In this breast cancer
model, NFAT induction has an impact on TGFβ tumor suppressor activ-
ity and promotes the tumor promoting effects by TGFβ, connected with
a nuclear accumulation of the SnoN transcriptional co-repressor that
blocks Smad nuclear activity in a gene-speciﬁc manner. In the presence
of high NFAT levels, Smad3 was trapped to the cytoplasm and
this possibly rescued nuclear SnoN from proteasomal degradation, a
mechanism known to be induced by Smads [80].
The TGFβ–AP1 transcriptional module can also induce expression of
the transcriptional repressor Blimp1/PRMD1, previously studied in
mechanisms of breast cancer cell migration after activation of the
nuclear factor κ B (NFκB) pathway, which was recently shown to be
transcriptionally induced by TGFβ in NMuMG and breast cancer cells
and contribute to the EMT and migratory responses of these cells [81].
Blimp1 repressed the TGFβ family member bone morphogenetic pro-
tein 5 (BMP5), which promotes mammary epithelial differentiation by
actively repressing Snail expression [81]. Thus, the TGFβ–AP1 pathway
induces Blimp1, which allows the further transcriptional induction
of Snail by TGFβ, as the BMP5 pro-epithelial antagonist of TGFβ is
transcriptionally inactivated. This mechanism is reminiscent of earlier
studies that explained how BMP signaling counteracts the pro-EMT fea-
tures of TGFβ by targeting the function of the inhibitors of DNA binding
(ID) -1, ID-2 and ID-3 [82,83]. Thus, while BMP signaling upregulates ID
protein levels, TGFβ downregulates their expression, which is impor-
tant for the establishment of EMT and terminal myoﬁbroblastic differ-
entiation. Among all three ID family members, ID2 has been shown to
play more key functional roles in the antagonism of TGFβ-mediated
EMT induced by BMP signaling [82,83]. Interestingly, TGFβ utilizes the
AP1–JunB module to repress ID2 expression in mammary epithelial
cells [84]. Themolecular action of ID proteins that lack the basic domain
but retain their HLH domains and thus fail to directly bind to DNA, is
that they pair with DNA-bound bHLH transcription factors and thus in-
activate the function of the bHLH factor [85]. In agreement with this
general model of ID function, ID1 pairs with Twist1 to modulate its ac-
tivity during breast cancer metastasis [86] as discussed further in sec-
tion 11. But surprisingly, ID2 was shown to associate with the N-
terminal SNAG domain of Snail and thus inhibit the transcriptionalactivity of Snail on the integrin-β4 gene that is repressed by Snail [87].
The prediction of this model is that during BMP signaling, ID2 levels in-
crease and promote epithelial differentiation in part by inactivating
Snail function, thus allowing expression of the pro-epithelial integrin-
β4. More recently, another gene target of the BMP–TGFβ antagonism
in breast cancer was characterized, the integrin-β3 subunit, which (in
contrast to β4) is induced by TGFβ via AP1/JunB complexes [84], and
downregulated by BMP signaling, and when integrin-β3 is artiﬁcially
overexpressed, it bypasses the pro-epithelial and anti-invasive actions
of BMP signaling [88]. It is worth noting that the majority of studies
where BMPs antagonize TGFβ in the context of EMT and breast cancer
metastasis, BMP7 appears to showmore potent activitywhen compared
to other BMP familymembers. Based on thismechanistic understanding
it makes good sense that BMP ligands have been successfully utilized to
counteract the pro-invasive and pro-metastatic effects of TGFβ and thus
have been proven therapeutically important in breast cancer models of
metastasis in vivo [89].
A ﬁnal example of transcriptional mechanisms that preserve the
epithelial phenotype and thus counteract the process of EMT, relates
to the tumor suppressor protein p53 and makes a link to the regulation
of EMT bymicroRNAs (miRNAs). TP53 directly regulates the expression
of the miR-200c, which is a central negative regulator of the EMT-TF
ZEB1 [90]. Thus, p53 promotes epithelial differentiation, the MET, and
in breast cancers where p53 is mutated and loses normal activity, the
loss of proper regulation of miR-200c is important for the loss of epithe-
lial homeostasis and the progression towards EMT. A second miRNA
target of p53 is miR-34, whose expression is maintained by wild type
p53 in normal epithelial tissues and repressed in cancer with loss-of-
function mutation of p53, including breast cancers [91]. One of the
direct targets of miR-34 is Snail, whereby Snail expression is silenced
in epithelial cells due to the action ofmiR-34. Loss of p53 leads to down-
regulation of miR-34 and release of Snail from this post-transcriptional
control mechanism [91,92]. The action of p53 is also relevant to one of
the favorite EMT models downstream of TGFβ, the NMuMG cells.
NMuMG cells express two p53 alleles, a wild type and a point mutant
(R277C) p53, and genetic downregulation of both copies of p53
in these cells promotes the TGFβ-mediated EMT, whereas nutlin3-
mediated stabilization of p53 counteracts TGFβ's pro-EMT effects [93].
Interestingly, recent studies in p53-null cancer cells demonstrated a
novel activity of nutlin-3 that blocked Smad2/3 phosphorylation by
the TGFβ type I receptor, causing overall weaker TGFβ signaling and
correspondingly weaker transcriptional upregulation of Snail and Slug,
thus blocking the EMT response in a p53-independent manner [94].
The direct target of the nutlin-3 inhibitory mechanism uncovered by
this study remains to be determined. Furthermore, p53 null breast
cancers, in addition to their EMT features are classiﬁed as claudin-low
breast cancers and are characteristically enriched in cancer stem cells
[95]. Thus, p53-mediated mechanisms that preserve epithelial homeo-
stasis center on the control of mammary epithelial differentiation at
the level of miRNAs.
6. Post-transcriptional and translational networks control the EMT
program downstream of TGFβ
The key role of miRNAs in controlling the EMT–MET processes in
mammary cells were brieﬂy discussed above. Since this topic has been
reviewed extensively [96,97], we will only highlight some more key
elements of the process and then focus onmore recently understood ex-
amples that expand the importance of post-transcriptional mechanisms
in the control of EMT and their relationship to TGFβ signaling. Themost
prominent miRNA gene family linked to the control of EMT-MET is the
miR-200 that includes the ﬁve members miR-200a, -200b, -200c, -141,
-429, and themiR-205 [96,97]. Expression of thesemiRNAs is repressed
by TGFβ signaling during the onset of EMT. This makes sense as two of
the most potent targets of miR-200 are the 3′-UTRs of the mRNAs for
the EMT-TFs, ZEB1 and ZEB2, which are downregulated by the miRNAs
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family, conditions for derepression of ZEB1 and ZEB2 are generated. In
addition, TGFβmust send signals to transcriptionally induce expression
of new ZEB1/ZEB2 mRNA levels. The newly identiﬁed mechanism by
which the ubiquitin ligase CUL4A regulates chromatin remodeling
at the ZEB1 promoter in breast cancer cells [98], may be relevant to
the complete understanding of ZEB1/2 transcriptional and post-
transcriptional regulation. ZEB1 and ZEB2 then repress miR-200 family
gene expression, thus establishing a double negative regulatory loop
[97]. Interestingly, for a prolonged EMT to persist in breast cancer,
sustained autocrine TGFβ ligand production is necessary, causing
among other thingsmethylation of the gene locus of themiR-200 family
leading to stable repression of the gene via the action of ZEB1 and ZEB2
[99]. Sustained autocrine TGFβ is not only important for the prolonged
establishment of EMT but also for the gain of stem-like features by
breast cancer cells as discussed later [40]. Interestingly, prolonged auto-
crine TGFβ signaling is sufﬁcient to bypass the growth inhibitory effects
in mammary epithelial cells and to promote the EMT and invasiveness
effects [40]; obviously such effects of prolonged autocrine TGFβ are eas-
ier to occur in the presence of oncogenic activities such as that ofmutant
Ras [43]. The latter can be established in part by at least two comple-
mentary mechanisms: a) ZEB1 directly represses the pro-oncogenic
transcription factor MYB, and in doing so limits the proliferative poten-
tial of breast cancer cells undergoing EMT [100]; b) during mammary
EMT induced by TGFβ, Smad complexes cooperate with the oncogenic
transcription factorMyc and bind together to Snail promoter sequences,
leading to Snail induction and EMT [101]. Snail induction by Myc pre-
cedes the robust downregulation of Myc by TGFβ–Smad signaling that
is necessary for the concomitant cell growth arrest that accompanies
the EMT process.
In addition to themiR-200 family, othermiRNAs have been linked to
the EMT process. miR-34 was discussed above and two more examples
have recently surfaced: a) similar to the miR-200/ZEB1/2 double
negative loop, miR-203 forms a regulatory loop with Slug during
TGFβ-induced EMT in breast cancer cells [102]. MiR-203 downregulates
post-transcriptionally Slug, and Slug potently represses miR-203
expression by binding to the miR-203 promoter, thus enforcing a
prolonged silencing of miR-203, so that Slug can accumulate and EMT
can proceed during sustained TGFβ signaling. b) The differentiation
transcription factor C/EBPβ is necessary for the maintenance of
mammary epithelia, and its expression is negatively regulated post-
transcriptionally by miR-155 [103]. The pro-epithelial function of
C/EBPβ is explained by the direct transcriptional induction of epithelial
genes, such as E-cadherin and coxsackie virus and adenovirus receptor
(CAR) that produce proteins critical for adherens and tight junctional
complexes, respectively. Low C/EBPβ levels characterize triple negative
breast cancers and induction of miR-155 by TGFβ seems to underlie the
loss of C/EBPβ in the mammary gland [103]. Regulation of miRNA
expression by miRNAs can also contribute to the control of EMT and
breast cancer stemness, as is the case of miR-22, which promotes EMT
and mammary stemness in vivo followed by enhanced metastasis
[104]. This miRNA functions by targeting the chromatin regulator Ten
eleven translocation (TET), which is required for cytosine demethyla-
tion, and acts speciﬁcally on the promoter of the miR-200 gene. Thus
miR-22 suppresses the pro-epithelialmiR-200 and in thiswaypromotes
the EMT and metastatic potential of breast cancer.
MiRNAs represent only a small proportion of the large collection on
non-coding RNAs (ncRNAs) that are abundantly transcribed in all cell
types, including breast. Very recent reports implicate for the ﬁrst time
the so-called long non-coding RNAs (lncRNAs) in the process of EMT
downstream of TGFβ. A major function of lncRNAs is the regulation of
chromatin organization and gene expression. Accordingly, the lncRNA
Hotair is transcriptionally induced by TGFβ in breast cancer cells and
is required for the EMT and associated cancer stem cell enrichment
[105]. Hotair expression is also enriched in metastatic breast cancer;
however, the mechanism of action of Hotair to elicit EMT remainscurrently uncharacterized. A genome-wide screen for lncRNAs recently
identiﬁed several of these genes being upregulated by Twist1 in
mammary epithelial cells undergoing Twist1-dependent EMT [106].
Future studies are awaited to explain how lncRNAs are implicated in
EMT and the process of breast cancer metastasis.
Another molecular mechanism involved in EMT downstream of
TGFβ is the regulation of alternative mRNA splicing. The best character-
ized case relates to the epithelial splicing regulatory proteins (ESRPs) 1
and 2, which induce the speciﬁc splicing pattern of mRNAs, including
those of FGF receptors that mediate terminal myoﬁbroblast differentia-
tion during TGFβ-induced EMT [107,108]. Interestingly, TGFβ induces
ZEB1 and ZEB2 expression, which then repress directly the ESRP2 gene
during EMT [108]. Additional RNA-seq analyses have identiﬁed another
cohort of regulators of alternative splicing during EMT in breast cancer,
including the proteins RBFOX, MBNL, CELF and more [109]. In contrast
to ESRPs, which are downregulated during EMT, RBFOX2 is upregulated
during EMT and leads to new splicing variants of mRNAs encoding for
the polarity protein Par3, the cytoskeletal protein cortactin and the
trafﬁcking regulator dynamin-2 [110]. The function of RBFOX2 appears
so far to link more with breast cancer invasiveness than with the onset
of EMT per se. This area of EMT research is still wide open and promises
interesting newmechanistic insight into the complexity of the program
that leads to invasive mesenchymal cells in breast cancer.
Further into post-transcriptional mechanisms of EMT, analysis of
ribosome-bound mRNAs revealed a number of years ago the induction
of synthesis of proteins such as interleukin-like EMT inducer (ILEI)
and the trafﬁcking adaptor Dab2 by TGFβ signaling in breast cancer
cell models undergoing EMT [111,112]. TGFβ signaling via the
non-Smad AKT2 pathway causes phosphorylation of the heterogeneous
nuclear ribonucleoprotein E1 (hnRNP E1), which then dissociates from
a speciﬁc motif located in the 3′-UTR of the ILEI and Dab2 mRNAs,
thus causing translational derepression and induction of de novo
synthesis of these two critical for the EMT program proteins [112].
HnRNP E1 represses mRNA translation by sequestering the activity of
the translational regulator eukaryotic elongation factor 1 A1 (eEF1-
A1) and thus stalling ribosomal elongation at the 3′-UTR prior to
completion of protein synthesis [113]. More recent genome-wide RNA
immunoprecipitation followed by microarray analysis revealed several
additional mRNAs that are translationally regulated in a similarmanner
as ILEI and Dab2 [114]. Interestingly, the HMGA2 and ZEB2 EMT-TFs are
included in this cohort of mRNAs. All the above mechanistic examples
emphasize the fact that EMT is a global process of change in cellular
organization that includes modulation of essentially every step in the
transfer of molecular information from genes to proteins and vice versa.
7. Effector programs of TGFβ that establish EMT
All previous regulatory mechanisms aim at providing a new pool of
proteins and RNAs that coordinate together with metabolic changes
the progressive transition of differentiation from the epithelial to
the mesenchymal cell phenotype. The functionally necessary protein
changes include secreted signaling proteins, matrix constituents,
adhesion components and cytoskeletal elements (Fig. 1). In this and
the next sections, we discuss selected molecules by emphasizing ECM
and adhesion proteins or glycosaminoglycans giving also emphasis to
the processes of protein glycation. This topic has recently been reviewed
inmore detail [115]. TGFβ itself utilizes a potent co-receptor, the type III
receptor or β-glycan that is a cell surface proteoglycan with a short
intracellular domain [46]. Interestingly, most of the examined breast
cancers underexpress β-glycan and the loss of its expression correlates
with the stage of the breast cancer so that the more advanced andmet-
astatic breast cancers almost completely lose expression of β-glycan
[116]. Artiﬁcial overexpression of β-glycan in human breast cancer cell
lines led to a relative decrease in invasive and metastatic potential,
which has been explained based on the shedding of the extracellular
domain of β-glycan, which then serves as a trap of TGFβ ligand in the
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soluble ectodomain of β-glycan limits TGFβ signaling towards immune
cells in the tumor microenvironment, including dendritic cells and
regulatory T lymphocytes, and thus the loss of β-glycan expression
in advanced breast cancers allows a more robust suppression of
anti-tumor immunity and gives an advantage for tumor growth and
dissemination [117]. However, membrane-bound β-glycan can also
function antagonistically to pro-invasive TGFβ signaling because
β-glycan's short C-terminal tail forms a complex with the adaptor
protein β-arrestin which then activates the small GTPase Cdc42 and
thus blocks breast cancer cell migration [118].
In general, the ECM response during EMT entails major changes in
collagen composition and speciﬁc upregulation of ﬁbronectin and
speciﬁc integrin receptors as already outlined in a previous section of
this article and reviewed by others [3,5]. In particular ﬁbronectin is con-
sidered a hallmark of themesenchymal phenotype [3,24]. Only recently
speciﬁc mechanistic clues have been revealed regarding a more direct
(and not a bystander) role of ﬁbronectin in the maintenance of EMT
[119]. Exposure of immortalized human mammary epithelial MCF-10A
cells (another frequent model of EMT studies) to ﬁbronectin or speciﬁc
fragments of ﬁbronectin, demonstrated a rather faithful induction of the
EMT program including adhesion protein remodeling, EMT-TF induc-
tion and further ﬁbronectin synthesis [119]. This mammary epithelial
response to ﬁbronectin in part utilized as signaling mediators integrins,
TGFβ receptors and the intracellular kinases Src and MAPK. It is thus
possible, that ﬁbronectin is induced by TGFβ during EMT and upon
synthesis and extracellular deposition, this ﬁbronectin further sustains
TGFβ signaling by contributing to the activation phase of the extracellu-
lar TGFβ ligand.
One of the deﬁning features of cell surface and ECM proteins is their
high content of glycation, either in the formofN- orO-linked sugar chains.
Dynamicmodulation of the state of glycation of proteins during their bio-
synthesis or secretion is well established, but speciﬁc functions of such a
dynamic regulation in the context of EMT are sparse and correlative. A re-
cent study focusing on the enzyme N-acetylglucosaminyltransferase III
demonstrated that the expression of this transferase is downregulated
by TGFβ during mammary EMT, while N-acetylglucosaminyltransferase
V expression is upregulated in mesenchymal cells [120]. The functional
role of N-acetylglucosaminyltransferase III at least in part is to modulate
the glycation state of E-cadherin in epithelial adherens junctions and
thus prolonging their stability and the homeostatic maintenance of the
epithelial state, thus explaining why TGFβ downregulates this enzyme
during EMT, when E-cadherin turnover is enhanced to mediate
junctional dissociation. Additional secreted or cell surface proteins play
regulatory roles during the EMT process. The membrane associated
signal peptide-CUB-EGF domain-containing protein 2 (SCUBE2)
which behaves as a breast tumor suppressor possibly by promoting
E-cadherin and adherens junction stability, suppressing β-catenin
nuclear accumulation and thus blocking migration and breast cancer
invasiveness [121]. TGFβ downregulates SCUBE2 by mobilizing DNA
methyltransferase I (DNMT1) to the SCUBE2 promoter, thus enforcing
methylation and silencing of this gene during EMT. In EpRas cells
where EMT depends exclusively on a sustained autocrine TGFβ signal,
TGFβ pro-EMT signaling seems to depend on semaphorin-7a, as the
depletion of semaphorin-7a makes EpRas cells resistant to EMT despite
the continuous autocrine TGFβ signal [122]. Interestingly, an endoge-
nous factor that can control the response of breast cancer cells to TGFβ
and semaphorin-7a is the transcription factor Ets2-repressor factor
(ERF), which actively represses the sempahorin-7a gene and thus
enforces stable epithelial differentiation in EpRas cells, fully bypassing
the activity of oncogenic Ras and autocrine TGFβ [122]. Similar to ERF,
another Ets family transcription factor, ELF5, promotes mammary
epithelial differentiation because it transcriptionally represses the Slug
gene in normal and in breast cancer cells [123]. Thus, ELF5 suppresses
EMT and promotesMET and is required for normalmammary gland dif-
ferentiation in the mouse, while its expression must be downregulatedin advanced and metastatic breast cancers. Overt misexpression of
ELF5 in mouse breast cancer models potently suppresses metastatic
potential [123].
Associated with the dynamic remodeling of cell–cell junctions is the
process of invasionwheremajor changes in cell membrane architecture
are supported by association between membrane proteins with either
the cytoskeleton intracellularly or the ECM extracellularly. The result
is the formation of speciﬁc membrane structures that support invasive-
ness such as invadopodia and ﬁlopodium-like protrusions [124,125].
The EMT-TF Twist1 activates a major genetic program that supports
the synthesis of new proteins that assemble invadopodia in breast and
other cancer cell types [124]. A protein that modulates invadopodial
assembly is the focal adhesion scaffolding protein Hic-5, whose expres-
sion is upregulated by TGFβ during EMT [126]. Hic-5 upregulation is
required for ECM degradation by metalloproteases and invasion of
breast epithelial cells upon EMT, and the function of Hic-5 requires
Src-dependent tyrosine phosphorylation and cooperation with the
small GTPase RhoC. Thus, EMT promoted by TGFβ enhances the levels
of a key adaptor protein so that the assembly of novel adhesion com-
plexes in association with RhoC and actin microﬁlaments can generate
the invadopodia that promote breast cancer migration through the
ECM. Similar to Hic-5, the mesenchymal protein lipoma preferred
partner (LPP) is another adaptor protein of focal adhesions that forms
new assemblies with the microﬁlament regulator α-actinin into focal
adhesions upon TGFβ stimulation in breast cancer cells and thus,
promotes invasiveness [127]. Misexpression of LPP in breast cancer
correlates with the overexpression of the ErbB2 receptor. Another cell
surface receptor that signals after binding to ECM components, namely
collagen type I, is the receptor tyrosine kinase discoidin domain recep-
tor 2 (DDR2), which then activates the kinases Src andMAPK [128]. The
MAPK Erk2 directly phosphorylates Snail causing stabilization and
nuclear accumulation of this transcription factor. Collagen I signaling
via DDR2 does not initiate the EMT, but is required for sustained EMT
via prolonged stabilization of Snail. Thus, mesenchymal cells that
undergo EMT and start invading their local matrix, further activate
Snail via DDR2 signaling, a process necessary for metastatic dissemina-
tion in vivo [128].
To support the newly formed and invasiveness-promoting assem-
blies of the plasma membrane with the ECM and the cytoskeleton, a
profound remodeling of integrins is required during EMT [129]. This re-
modeling at least in part contributes to the activation of ECM-embedded
TGFβ in a sustainedmanner [130,131], which is critical for the EMT pro-
gram as explained above. Both integrinα and β subunits are remodeled
during EMT and this depends on the speciﬁc developmental origin of
the epithelial cell type. In breast cancer, transcriptional induction
of integrin-α3 has recently been established during EMT as a marker
of aggressive breast cancer [132]. Through their extensive studies on
this topic, recent work from the Schiemann laboratory has provided
an intriguing scenario of integrin subunit exchange during breast cancer
EMT, whereby loss of integrin-β1 is compensated by upregulation of
integrin-β3 [133]. Integrin-β3 upregulation not only contributes to
invasiveness and breast cancer metastasis in the mouse model exam-
ined, but also switches the response of breast cancer cells to TGFβ, so
that their growth is no longer inhibited and is even stimulated by the ac-
tion of this cytokine [133]. Not only integrin subunit expression is im-
portant during EMT and breast cancer metastasis, but TGFβ can also
induce the expression of the adhesion-related kinase Pyk2, a response
important for breast cancer cell invasion and metastasis in vivo [134].
The upregulation of Pyk2 in breast cancer cells correlates with the stabi-
lization of integrin-β1, both required for the invasive process of such
tumor cells. It becomes therefore increasingly clear, that the contextual
and dual roles of TGFβ signaling during breast cancer progression are
now rather well understood, and partake signiﬁcant remodeling of cell
surface and ECM components that communicate new signaling inputs
to breast epithelial cells as they transit to the more mesenchymal
phenotype.
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Hyaluronan is an anionic, non-sulfated linear glycosaminoglycan
comprised of repeating disaccharide units of glucuronic acid and
N-acetylglucosamine. Due to its high molecular mass and negative
charge it binds up to 1000-fold its weight of water forming loose and
elastic matrices that promote cell proliferation and migration
[135,136]. Elevated amounts of hyaluronan are found whenever there
is rapid tissue remodeling, i.e. during embryogenesis, inﬂammation
and cancer. Using immunohistochemistry, a strong correlation was
noticed between the presence of hyaluronan in peritumoral stroma
and cancer cells, and disease progression, in unselected clinical breast
cancer specimen [14]. However, despite this observation no correlation
between the presence of hyaluronan and disease outcomewas found in
node-negative breast cancer, rather, versican alone appeared to be a
predictor for node-negative cancer metastasis [22]. Notably, stromal
myxoid changes are characterized by high amounts of hyaluronan and
are associated with breast cancer invasion and metastasis [137].
Thus, although the ECM components hyaluronan and versican form
complexes, their expression levels vary between individual breast tu-
mors affecting differentially breast cancer progression. Furthermore,
sonographic examination of inﬁltrating breast carcinoma in comparison
to histologic sections of the same carcinomas stained for hyaluronan or
collagen, revealed a correlation between tumor shape and the shape of
extracellular hyaluronan, but not collagen [138].Most studies have been
performed on developing or fully developed malignancies, and not on
the early phases of the malignant process. During the early phase of
themalignant process, most likely epithelial–mesenchymal interactions
lead to deregulation of ECM molecules in the breast gland, whose
expression levels and later correlation to malignant progression in
breast tissue are not fully understood. Among the ECM components,
signiﬁcantly elevated levels of hyaluronan were detected in serum
from patients with metastatic carcinoma compared to non-metastatic
or benign breast carcinoma [139]. The functional signiﬁcance of
hyaluronan changes in distinct subtypes of breast cancer tissue stroma
and blood as a factor promoting malignant transformation remains to
be determined.
Genes that contribute to adverse breast cancer pathophysiologies
have been classiﬁed into the 50-gene signature termed PAM50
[140–142]. Besides this classiﬁcation, breast cancer can be classiﬁed
based on the expression of ECM components into four main groups
designated ECM1, 2, 3 and 4 [143]. Hyaluronan was predominantly
upregulated in tumors characterized by the ECM2 signature and repre-
sented one of the most clinically aggressive phenotypes, i.e. transition
between the aggressive luminal B and the less aggressive luminal A
phenotype [143]. This study further supports the hypothesis that
stromal characteristics are related to clinical outcome.
9. Finely tuned regulation of hyaluronan metabolism in
breast cancer
In healthy tissue the levels of hyaluronan are regulated by the coor-
dinated action of hyaluronan synthesizing enzymes (termed HAS1,
HAS2 and HAS3) and hyaluronidases (termed HYAL1, HYAL2, HYAL3
and PH-20), as well as by its rate of elimination. In general, hyaluronan
chains of a molecular mass higher than 400 kDa are found in healthy
tissues whereas smaller molecules, resulting from the action of hyal-
uronidases, are present during inﬂammation and cancer progression
[136,144,145]. Furthermore, in puberty during the growth of ductal
structures, the basementmembrane at the tip of the duct, i.e. at the inva-
sive front, is enriched in hyaluronan whereas the basement membrane
that surrounds ducts is composed of other ECM components including
collagen type IV and laminin [146]. In addition, during the formation of
chorioallantoic membrane capillaries hyaluronan-rich matrices at the
tip were rapidly repressed due the activation of hyaluronidases [147].
These observations support the notion that high molecular masshyaluronan suppresses, whereas fragmented hyaluronan, e.g. occurring
in chronic inﬂammatory foci, promotes angiogenesis. These data suggest
that a ﬁnely tuned regulation of hyaluronan production and degradation
can regulate the behavior of epithelial and endothelial cells, e.g. during
inﬂammation and oncogenesis.
Hyaluronanmediates its cellular signaling through interactionswith
speciﬁc cell surface receptors, such as CD44 and RHAMM (receptor for
hyaluronan mediated motility). A large number of studies have impli-
cated these receptors in regulation of cell proliferation, migration and
differentiation [148–153]. An interesting new study of breast cancer
metastasis demonstrated that one of themechanisms by whichmesen-
chymal stem cells that are recruited to sites of primary breast cancer
growth, promotemetastasis, is the induction of synthesis of the lysyl ox-
idase (LOX) by the breast cancer cells that respond to themesenchymal
cells [154]. Induction of metastatic potential by LOX requires the activa-
tion of breast cancer cell CD44 by extracellular hyaluronan, leading to
cleavage and nuclear translocation of the CD44 intracellular domain,
which then associates with the LOX promoter and enhances transcrip-
tion of the LOX gene. Induction of LOX in the breast cancer cells
then stimulates Twist1 expression (possibly via stabilization of Snail,
although not yet deﬁned), and subsequent EMT of the breast cancer
cells [154]. Such EMT of breast cancer cells induced by mesenchymal
stem cells could not be linked to the generation of breast cancer stem
cells (see below for further discussion).
The speciﬁc physiological functions of each one of the three HASes
are not yet understood; they differ in enzymatic properties and
activities, and respond differently to various exogenous stimuli, such
as growth factors and cytokines [155–158]. Recent studies revealed
that changes in hyaluronan production are not always due to changes
in HAS mRNA expression [158–160]; modulation of the synthetic rate
could also be due to posttranslational modiﬁcations of HAS molecules,
such as phosphorylation [160–162] and ubiquitylation [163], as well
as availability of the substrates [164]. All HASes are expressed in breast
cancer, but several studies have in particular implicatedHAS2 activity to
be closely correlated to breast cancer development and progression.
Whereas upregulation of either HAS1 or HAS2 most likely promotes
breast cancer, only HAS2 inhibition reduced the tumorigenicity in v-Ha-
Ras transformed cell lines [165]. Furthermore, overexpression of HAS2
in ErbB2-induced mammary tumors led to increased hyaluronan
production, which in turn induced the production of pro-angiogenic
factors accelerating angiogenesis [20]. During EMT, occurring during
breast adenocarcinoma progression, HAS2 expression plays a pivotal
role. Normal mammary epithelial cells infected with a HAS2 adenovirus
undergo EMT through upregulation of vimentin and loss of adhesion
proteins at intercellular junctions [166]. Recently, we demonstrated
that TGFβ-inducedHAS2 inmammary epithelial NMuMG cells is impor-
tant for the TGFβ-mediated EMT; silencing of HAS2 inhibited the TGFβ-
mediated EMT by about 50% and suppressed the expression of the EMT
markers ZO-1, ﬁbronectin, ZEB1 and Snail [167] (Fig. 2). Notably, during
zebraﬁsh development, HAS2 is crucial for cell migration through acti-
vation of the small GTPase Rac1, where HAS2-expressing cells migrate
whereas HAS2-negative cells remain stationary [168]. Rac1 activation
could be the result of the binding of HAS2-synthesized hyaluronan
to CD44 and subsequent interaction with the GTPase activating protein
IQGAP1 [169]. Furthermore, HAS2−/− mouse embryos lacking
hyaluronan, die during midgestation because of failure to undergo car-
diac morphogenesis and valve formation [170]. HAS2-synthesized
hyaluronan in the cardiac jelly induces PI3K and ErbB signaling in a
TGFβ-induced EMT [170]. Interestingly, miR-23 activity modulates car-
diac valve formation by inhibiting the TGFβ-induced HAS2 expression
and hyaluronan production [171]. The molecular mechanisms through
whichmiR-23, in a TGFβ-dependentmanner regulatesHAS2 expression
during mammalian valve formation remains to be elucidated. In addi-
tion, overexpression of HAS2 in aggressive mesotheliomas and colon
carcinomas increased their malignant and ﬁbroblast-like migratory
phenotype [172,173].
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and breast cancer progression has been further established using breast
cancer cell lines. Silencing of the HAS2 gene led to lower proliferative
capacity and decreased migratory and invasive capacity of Hs578T
cells, thus demonstrating the necessity of HAS2 expression for the
malignant phenotype of this invasive breast cancer cell line [174,175].
Most likely, HAS2-induced hyaluronan is rapidly depolymerized into
fragments of a size of 10–40 kDa that could promote tumor neovascu-
larization [149,175–177]. The importance of HAS2 for breast cancer
metastasis has been demonstrated in an intracardial and mammary fat
pad metastasis experimental model, where the decrease of HAS2
reduced organ metastasis [175]. Notably, soluble factors released in
breast cancer, such as osteopontin, TGFβ and platelet-derived growth
factor (PDGF)-BB, can both inﬂuence the regulation of HAS2 and also
bind cell surface receptors that in cooperation with the hyaluronan re-
ceptor CD44 affect several signaling cascades, leading to e.g. migration
and proliferation [151,174,178,179]. Although a comprehensive under-
standing of the role of HAS2-synthesized hyaluronan and the HAS2
molecule as such in breast cancer progression is not yet fully under-
stood, it is possible that HAS2 enhances breast cancer invasion by
suppression of the tissue inhibitor of metalloproteinases 1 (TIMP-1)
and by increase of epidermal growth factor (EGF)-mediated induction
of the FAK/PI3K/AKT signaling pathway [180]. Furthermore, increased
synthesis of hyaluronan might, through its interactions with versican,
create hydrated and expanded matrices that facilitate cancer–host
interactions and diffusion of nutrients [20], as well as recruitment of
immunosuppressive macrophages, decreasing the immune attack
on the tumor cells [181], and bypassing the repression of E-cadherin,
leading to suppression of EMT [182].
10. EMT and breast cancer stem cells
The pioneeringwork from the Clarke laboratory ﬁrst established the
concept of breast cancer stem cells (CSCs) that are usually identiﬁed as
populations of cells expressing high levels of the hyaluronan receptor
CD44 and low levels of the surface sialoglycoprotein CD24 [183]. This
was followed by the illuminating work of the Weinberg and Puisieux
laboratories that demonstrated that breast CSCs could be enriched
in populations that underwent EMT due to the high expression of
EMT-TFs, like Snail and Twist1 [7,8]. This concept is now veriﬁed in
many laboratories and is compatiblewith the process of reprogramming
that epithelial cells undergo during EMT [65,184]. Although clues to the
link between transcriptional and epigenetic control during EMT and the
generation of CSCs was brieﬂy introduced above, we here enlist a few
additional reports that attest to the generality of this molecular link.
Novel technology has generated the induced pluripotent stem cells
(iPSCs) after transfection of differentiated cells with speciﬁc transcrip-
tion factors that promote stemness, Oct4, Klf4, Myc and Sox2 [185].
During the iPSC protocol, time-dependent analysis has revealed that
an EMT program is ﬁrst initiated during induction of pluripotency,
marked by the upregulation of Slug and later followed by an MET step
that establishes the epithelial differentiation of the pluripotent stem
cells [186]. TGFβ signaling during the early EMT phase promotes
pluripotency, whereas the MET phase depends on BMP signaling and
upregulation of miR-200 family members that enforce the epithelial
phenotype [187]. These studies support the notion that reprogramming
during EMT is not only relevant to cancer but also has direct links
to the more physiological process of induced stemness and the genera-
tion of pluripotent stem cells. Furthermore, it appears that during
reprogramming of normal stem cells and cancer cells, cycles of EMT
and MET are important to occur, suggesting that these processes may
provide an adaptive force when cells change their differentiation poten-
tial. This is compatible with the ﬁndings that major developmental
signaling pathways, like TGFβ, BMP and Wnt mediate these transitions
and stemness in the context of both normal and tumor states in the
breast [188]. The same trend has been characterized for the EMT-TFFOXC2, which establishes the mesenchymal state of mammary cells
and contributes to CSC potential at least in part by inducing the
transcription of the PDGF β-receptor [189]. For this reason, a clinically
approved PDGF receptor inhibitor, sunitinib, was shown to limit the
CSC and metastatic potential of breast cancer cells with high FOXC2
expression. Yet another pathway that is critical for the generation of
the breast CSCs is the Hippo pathway and its downstream effector
protein TAZ, which when overexpressed and activated by Hippo
pathway kinases endows non-CSCs with CSC potential in the breast
[190]. One of the molecular functions of TAZ is to inactivate the function
of the epithelial polarity protein Scribble, thus causing EMT and promot-
ing stemness in breast cancer cells.
An important factor regulated by TGFβ and Wnt signaling in breast
cancer is the transcription factor Grainyhead-like 2 (GRHL2), which
associates with homeobox transcription factors like Six1, a positive reg-
ulator of ZEB1 expression, to block their function [191]. GRHL2 therefore
blocks EMT and limits the breast CSC potential, while sensitizing breast
cancer cells to classical chemotherapy; TGFβ and Wnt downregulate
GRHL2 promoting breast CSCs. In basal types of breast cancers with
gene ampliﬁcation of the TP63 gene, the corresponding protein product
ΔNp63 directly transactivates the gene for BMP7, which induces BMP
signaling and contributes to breast cancer stemness [192]. For this rea-
son, a BMP type I receptor inhibitor limits the breast CSC pool. A similar
study using the A17 mouse breast cancer model, demonstrated that the
BMP type I receptor inhibitor dorsomorphin limited the number of
breast CSCs and reverted these cells to a more epithelial state, and pro-
vided evidence for a role of mesenchymal stem cells being dependent
on active BMP signaling [193]. Although somewhat counterintuitive,
theseﬁndingsmay bear on the relevance of EMT–MET cycles as a critical
component for cancer stemness, and BMP7 might support the latter
transition following EMT. Furthermore, the EMT-TFs, like Twist1 and
ZEB1/2, interfere with key pathways, such as the p53, pRb and PP2A
phosphatase, thus preventing oncogene-induced senescence and apo-
ptosis and facilitating tumorigenic conversion by oncogenes, such as
Ras, to advanced stages that resemble the claudin-low group of breast
cancers that have characteristic enrichment in stem-like features
[194]. According to these schemes, breast CSCs arise via EMT and chang-
es in differentiation instead from arising aftermalignant transformation
of stem-like progenitor cell types in the mammary gland, and mecha-
nisms of suppression of cell death in a growing tumor tissue are of
importance for the generation of cancer cells with stem-like potential
[195].
Normal andmalignant stemcells are dependent on a tissuemicroen-
vironment often called the stem cell niche. Metabolic conditions in the
niche often provide the contextual cues that activate key pathways as
those described above that support cancer stemness. One of the
metabolic conditions that prevail in breast cancer niches is hypoxia. In
an interesting experimental protocol, breast cancer cells were exposed
to cycles of hypoxia and normoxia and the pool of breast CSCs and
their self-renewal capacity was monitored [196]. The cyclic protocol
allowed the enrichment of the cell population in CSCs with enhanced
tumor-initiating potential in mouse transplantation experiments.
Hypoxia affects multiple molecular pathways, one being the Notch
ligand Jagged2 that causes EMT and promotes breast CSC growth;
consistent with this observation, Jagged2 expression and active Notch
signaling have been found to correlate with poor prognosis and metas-
tasis of human breast cancers [197]. In the breast cancer niche, hypoxia
causes changes in local pH, in part mediated by the hypoxia-inducible
protein carbonic anhydrase IX (CAIX) [198]. The function of CAIX in
breast cancer causes activation of mTORC1 signaling leading to EMT
and high expression of Jagged1 and Notch1, which contribute to breast
CSC proliferation. Such breast CSCs were eradicated from mice treated
with an inhibitor of CAIX, and combination therapy with paclitaxel
and the CAIX inhibitor potently blocked metastasis in these mice
[198]. A pathway related to hypoxia is themitochondrial retrograde sig-
naling mechanism that involves the phosphatase calcineurin, which
2630 A. Moustakas, P. Heldin / Biochimica et Biophysica Acta 1840 (2014) 2621–2634causes breast EMT and generation of CSCs [199]. This pathway provides
novel chances for therapeutic intervention of breast cancer metastasis
and is initiated by changes in the copy number of mitochondrial DNA,
often observed in human breast cancers.
In addition to hypoxia, other factors in the CSC niche inﬂuence the
proliferation and survival of breast CSCs. The balance between endothe-
lial and mesenchymal progenitors, including adipose stromal cells
has an impact on breast cancer progression in transplanted mice, and
mediate EMT, as well as tumor-promoting angiogenesis, leading to
enhanced metastatic potential [200]. These ﬁndings are relevant to the
clinical observations whereby obese breast cancer patients exhibit
enhanced chances for advanced disease includingmetastasis and earlier
death. Acquisition of CSC potential via the EMT process may also have
other important effects that are relevant to cancer progression. For ex-
ample, breast cancer cells exhibiting EMT showed enhanced resistance
to the cytolytic action of cytotoxic T lymphocytes [201]. The resistance
was due to the lack of the development of a normal immunogenic
synapse between T cells and tumor cells, while breast cancer cells
with overt EMT exhibited enhanced autophagic behavior. The autopha-
gy regulator Beclin1 was shown to be important as genetic ablation of
this protein allowed cytotoxic T cells to lyse the EMT breast cancer
cells because of the lack of the autophagic behavior by the tumor cells
[201].
A corollary of the concept of CSCs is the development of technologies
to detect them in the blood of breast cancer patients and utilize them as
prognostic means to predict disease outcome. Interestingly, one of the
ﬁrst comprehensive analyses of circulating tumor cells in breast cancer
patients found a diverse cohort of cells exhibiting both epithelial and
mesenchymal features [202]. Circulating mesenchymal cells correlated
with worse disease outcome and exhibited active molecular markers
of EMT, including, TGFβ signaling intermediates and EMT-TFs. Thus
the concept of EMT linking to cancer stemness provides advanced po-
tential for both novel therapeutic intervention and prognostic means
in human breast cancer.
11. EMT–MET and the process of metastasis
The correlation between EMT and breast cancer metastasis has
already been discussed above. In this section, we aim at emphasizing
novel evidence that clariﬁes that what is most relevant for metastasis
is the cyclic EMT–MET transition. EMT–MET provides new epithelial
cancer cells that, after undergoing the EMT, obtained enhanced capaci-
ties that make them capable of seeding properly to newmetastatic sites
and promoting the spread of the disease. The homeobox transcription
factor Prrx1 is a newly identiﬁed inducer of EMT [203]. Despite an en-
hanced invasive potential by cells that overexpress Prrx1, this factor
must be downregulated for cancer cells to achieve metastatic coloniza-
tion and as a consequence themetastatic cells undergoMET and acquire
epithelial features. This is one of the ﬁrst molecular examples that
explain why most metastatic carcinomas appear epithelial and lack
the morphological features of mesenchymal cells. In a more convincing
experimental set up, the Yang laboratory studied conditional expression
of Twist1 in a mouse model of spontaneous skin cancer induced by
chemical carcinogens [204]. Using elegant time-dependent activation
of the Twist1 transgene, it was shown that while Twist1 expression
was required for the induction of EMT and local invasive cancer,
efﬁcient metastatic colonization required the silencing of Twist1 to
allow reversion of EMT so that blood-borne circulating tumor cells
could generate new colonies of epithelial phenotype [204]. Together
with the Prrx1 study, this study emphasizes the functional importance
of EMT as a transient process thatmust be followed byMET ifmetastasis
is to succeed. In accordance with the above two studies, a novel role of
ID1 has recently been revealed during breast cancer metastatic coloni-
zation [86]. In primary breast cancer, TGFβ induces Snail and EMT as
previously established. TGFβ can then induce ID1 in mesenchymal
cells produced by the EMT process and this ID1 binds and inactivatesTwist1, causingMET and functionally promoting the epithelial coloniza-
tion at the metastatic site [86]. In this intriguing model, ID1 in the
primary breast cancer does not affect the EMT and invasiveness of the
cells. The work establishes the ID proteins as keymediators of plasticity
at distinct sites of tumor growth. Based on the complexity of the
EMT–MET cycle during breast cancer progression and the impact that
TGFβ signaling has at multiple steps of this cycle, it is anticipated that
therapeutic intervention against breast cancer metastasis by targeting
the EMT–MET process or TGFβ signaling will be complicated and possi-
bly unsuccessful [24,205].
12. Conclusions
In the previous sections we presented speciﬁc examples and exper-
imental evidence that clearly link cytokine and glycosaminoglycan
signaling to the process of EMT in the context of breast cancer. Due to
the focus of our own work, emphasis has been given to TGFβ and
hyaluronan, however, wherever appropriate we made reference to
other relevant regulators of the EMT process. The current state of the
art clearly suggests that deeper understanding is required for the com-
plete elucidation of mechanisms by which cytokine signaling crosstalks
withmajor constituents of the ECM tomodulate the process of EMT, cell
invasiveness and metastasis. In particular the contribution of such
mechanisms to the generation and maintenance of breast cancer stem
cells is even more poorly understood and deserves further analysis. Fi-
nally, the recent studies that establish the necessity of the EMT–MET
cycle for both cancer stem cell generation andmetastatic dissemination,
provide new ground for future investigations that will clarify in a more
quantitative and integrative manner the sequential process that leads
from primary tumor to the deadly phase of metastatic growth. Based
on this scheme, molecular studies of ECM components, signaling path-
ways, various non-coding RNAs and epigenetic mechanismsmost likely
will remain at the forefront of the ﬁeld as experimentalists seek new
biomarkers and therapeutic protocols to assist patients with breast
cancer.
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